NRSN — NeuroSense Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875091 ·
Last close
$3.66
Market Cap
$6.94M
52W High
$11.56
52W Low
$0.25
ADV30
253,565
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,028,000 | 166,000 | 2,588,000 |
| Jun 2025 | — | — | — | — | 1,684,000 | 666,000 | 2,203,000 |
| Dec 2024 | 0 | — | -1,771,000 | -1,801,000 | 4,575,000 | 3,378,000 | 1,992,000 |
| Sep 2024 | 0 | — | -2,107,000 | -2,148,000 | 984,000 | 344,000 | 3,802,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-47,785,000
Inventory
—
Receivables
$33,000
ST Investments
—
EBIT TTM
$-1,771,000
Pretax Income TTM
$-1,801,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,085,000 | -11,125,000 | 1,028,000 | 2,588,000 | -1,560,000 | -7,671,000 |
| Dec 2024 | 0 | -9,902,000 | -10,210,000 | 4,575,000 | 1,992,000 | 2,583,000 | -10,135,000 |
| Dec 2023 | 0 | -12,049,000 | -10,107,000 | 3,185,000 | 4,944,000 | -1,759,000 | -8,354,000 |
| Dec 2022 | 0 | -10,554,000 | -10,492,000 | 7,710,000 | 2,091,000 | 5,619,000 | -7,616,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-13.50
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LEXX | Lexaria Bioscience Corp. | $6.99M | $3.32 | — |
| XCUR | EXICURE, INC. | $6.87M | $1.05 | — |
| TRAW | Traws Pharma, Inc. | $6.84M | $0.45 | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $6.56M | $0.50 | — |
| ENVB | Enveric Biosciences, Inc. | $6.49M | $1.45 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroSense Provides Update on Nasdaq Listing Compliance
2026-10-02 20:15 · Yahoo
NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
2026-09-28 16:43 · Yahoo
NeuroSense Provides Business Update and Progress for the First Half of 2026
2026-09-25 20:30 · Yahoo
NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference
2026-09-10 13:00 · Yahoo
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
2026-08-31 12:45 · Yahoo
NeuroSense Issues CEO Letter to Shareholders
2026-08-13 13:30 · Yahoo
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
2026-08-06 15:29 · Yahoo
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
2026-07-22 12:30 · Yahoo
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
2026-07-06 12:45 · Yahoo
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
2026-06-29 13:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.